Centers for Disease Control and Prevention (CDC). National Kidney Disease Fact Sheet. General Information and National Estimates on Chronic Kidney Disease in the United States, 2014. Atlanta, GA, US Department of Health and Human Services Centers for Disease Control and Prevention, 2014.

• PubMed
Centers for Disease Control and Prevention (CDC). National Kidney Disease Fact Sheet. General Information and National Estimates on Chronic Kidney Disease in the United States, 2014. Atlanta, GA, US Department of Health and Human Services Centers for Disease Control and Prevention, 2014.)| false
• Search Google Scholar
• Export Citation

US Renal Data System. USRDS 2015 Annual Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases, 2013.

• PubMed
US Renal Data System. USRDS 2015 Annual Report. Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases, 2013.)| false
• Search Google Scholar
• Export Citation

Medicare Improvements for Patients and Providers Act, Pub 1 No. 110–275, 122 Stat 2553, 2008.

• PubMed
Medicare Improvements for Patients and Providers Act, Pub 1 No. 110–275, 122 Stat 2553, 2008.)| false
• Search Google Scholar
• Export Citation

Hirth RA , et al.. The initial impact of Medicare’s new prospective payment system for kidney dialysis patents. Am J Kidney Dis 2013; 62:662–669.

• PubMed
Hirth RA , . The initial impact of Medicare’s new prospective payment system for kidney dialysis patents. Am J Kidney Dis 2013; 62:662–669.)| false
• Search Google Scholar
• Export Citation

Palmer SC , Sciancecalepore M , Strippoli GFM . Trial quality in nephrology: How are we measuring up? Am J Kidney Dis 2011; 58:335–337.

• PubMed
Palmer SC , Sciancecalepore M , Strippoli GFM . Trial quality in nephrology: How are we measuring up? Am J Kidney Dis 2011; 58:335–337.)| false
• Search Google Scholar
• Export Citation

Morgan S , et al.. The cost of drug development: A systematic review. Health Policy 2011; 100:4–17.

• PubMed
Morgan S , . The cost of drug development: A systematic review. Health Policy 2011; 100:4–17.)| false
• Search Google Scholar
• Export Citation

How the Tufts Center for the Study of Drug Development Pegged the Cost of a New Drug at $2.6 Billion, Boston. The Tufts Center for the Study of Drug Development, 2014.

• PubMed
How the Tufts Center for the Study of Drug Development Pegged the Cost of a New Drug at $2.6 Billion, Boston. The Tufts Center for the Study of Drug Development, 2014.)| false
• Search Google Scholar
• Export Citation

Avorn J . The $2.6 billion pill—methodological and policy considerations. N Engl Med 2015; 372:1877–1879.

• PubMed
Avorn J . The $2.6 billion pill—methodological and policy considerations. N Engl Med 2015; 372:1877–1879.)| false
• Search Google Scholar
• Export Citation

DiMasi JA , Grabowski HG , Hansen RW . The cost of drug development. New Engl J Med 2015; 372:1972.

• PubMed
DiMasi JA , Grabowski HG , Hansen RW . The cost of drug development. New Engl J Med 2015; 372:1972.)| false
• Search Google Scholar
• Export Citation

Kidney Health Initiative Inaugural Review 2012–2014. https://www.asn-online.org/khi/KHI_YER_2014.pdf.

• PubMed
Kidney Health Initiative Inaugural Review 2012–2014. https://www.asn-online.org/khi/KHI_YER_2014.pdf.)| false
• Search Google Scholar
• Export Citation

Thompson A , Lawrence J , Stockbridge N . GFR decline as an end point in trials in CKD: A viewpoint from the FDA. Am J Kidney Dis 2014; 64:836–837.

• PubMed
Thompson A , Lawrence J , Stockbridge N . GFR decline as an end point in trials in CKD: A viewpoint from the FDA. Am J Kidney Dis 2014; 64:836–837.)| false
• Search Google Scholar
• Export Citation

Levey AS , et al.. GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014; 64:821–835.

• PubMed
Levey AS , . GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2014; 64:821–835.)| false
• Search Google Scholar
• Export Citation

European Medicines Agency. Draft Guidelines on the Clinical Investigation of Medicinal Products to Prevent Development/Slow Progression of Chronic Renal Insufficiency (EMA/CHMP/355988/2014).

• PubMed
European Medicines Agency. Draft Guidelines on the Clinical Investigation of Medicinal Products to Prevent Development/Slow Progression of Chronic Renal Insufficiency (EMA/CHMP/355988/2014).)| false
• Search Google Scholar
• Export Citation